Prostate Cancer Clinical Trials

The Vermont Cancer Center has many trials focused on prostate cancer research.

Status: Active - Recruiting
Study Title:
Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients With High-Risk, Clinically Localized Prostate Cancer

Purpose: This randomized phase III trial is studying docetaxel and leuprolide or goserelin to see how well they work when given before surgery compared with surgery alone in treating patients with high-risk localized prostate cancer.

ClinicalTrials.gov Identifier: NCT00430183
Primary/Site/Co Investigator: Steve Ades, MD
Contact: Deb McAdoo (802) 656-9113
Information: http://clinicaltrials.gov/ct2/show/record/NCT00430183?term=calgb+90203&rank=1
Institution Number: M95-106, CALGB 90203
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate and Favorable High-Risk Prostate Cancer: A Phase III Randomized Trial
Purpose: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.
ClinicalTrials.gov Identifier: NCT01368588
Primary/Site/Co Investigator: H. James Wallace, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT01368588?term=RTOG+0924&rank=1
Institution Number: M12-222, RTOG 0924
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title:
A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Purpose: This randomized phase III trial is studying prostate radiation therapy to see how well it works compared with short-term androgen deprivation therapy given together with pelvic lymph node radiation therapy with or without prostate radiation therapy in treating patients with a rising PSA after surgery for prostate cancer.
ClinicalTrials.gov Identifier: NCT00567580
Primary/Site/Co Investigator: H. James Wallace, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://www.clinicaltrials.gov/ct2/show/NCT00567580?term=RTOG+0534&rank=1
Institution Number: 97-7 RTOG 05-34
Protocol Research Type: Cooperative Group
Status: Active - Recruiting
Study Title: RTOG 1115 – Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate Cancer
Purpose: One of the common treatments for men with high risk prostate cancer includes radiation therapy and androgen deprivation with an LHRH agonist and antiandrogen (commonly called “hormone therapy”). The purpose of this study is to compare the effects of standard hormone therapy and radiation therapy with standard hormone therapy plus TAK-700 and radiation therapy on you and your prostate cancer to find out which is better. This study is testing if the combination of 3 drugs (LHRH agnonist, antiandrogen and TAK-700) further suppresses the action of testosterone and leads to an improved chance to cure your prostate cancer
ClinicalTrials.gov Identifier: NCT01546987
Primary/Site/Co Investigator: H. James Wallace, MD
Contact: Jennifer Holmes (802) 847-3453
Information: http://clinicaltrials.gov/ct2/show/NCT01546987?term=RTOG+1115&rank=1
Institution Number: CHRMS M14-004 / RTOG 1115
Protocol Research Type: Cooperative Group
Status: Active - Closed to Accrual
Study Title: Treatment Choices of Men with Good-Risk Prostate Cancer
Purpose: This study will involve men with good-risk prostate cancer and their clinicians. The study will occur in two phases. First, clinicians will be asked to complete a one-time interview regarding their experiences and clinical reasoning when treating men with good-risk prostate cancer (Aim 1). Also, approximately 40 men (10 of the 40 from UVM) will be asked to complete a one-time interview about their feelings and knowledge regarding their cancer diagnosis and treatment options and the things they considered when making a decision about treatment (Aim 1).
ClinicalTrials.gov Identifier: N/A
Primary/Site/Co Investigator:
Contact: Deb McAdoo (802) 656-9113
Information: N/A
Institution Number: M13-054
Protocol Research Type: Investigator Initiated
Status: Active - Closed to Accrual
Study Title: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL 184) vs. Prednisone in Metastatic Castration-resistant Prostate Cancer Patients who have Received Prior Docetaxel and Prior Abiraterone or MDV3100. 
Purpose: The purpose of this study is to evaluate the effect of cabozantinib compared to prednisone on overall survival in men with previously treated metastatic castration-resistant prostate cancer with bone-dominant disease who have experienced disease progression on Docetaxel-containing chemotherapy and Abiraterone or MDV3100 (enzalutamide). 
ClinicalTrials.gov Identifier: NCT01605227
Primary/Site/Co Investigator: Steven Ades, MD
Contact: Kate Murray (802) 656-9401
Information: http://clinicaltrials.gov/ct2/show/NCT01605227?term=Comet-1&rank=1
Institution Number: M13-079
Protocol Research Type: Industry Sponsored